Post-TAILORx, Genomic Health Tightens Focus on International Expansion

NEW YORK (GenomeWeb) – With the long-awaited results from the TAILORx trial now public, Genomic Health is shifting attention and resources back to its core breast cancer test in an attempt to capitalize on a wave of public attention and take advantage of new openings the study has made into international markets.

Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Be the first to comment

Leave a Reply

Your email address will not be published.